Journal
CURRENT OPINION IN VIROLOGY
Volume 35, Issue -, Pages 57-62Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2019.04.002
Keywords
-
Categories
Funding
- National Institutes of Health [U19 AI109680, R01 AI132178, R01 AI108197]
Ask authors/readers for more resources
Recent outbreaks of SARS-Coronavirus and M ERS-Coronavirus (CoV) have heightened awareness about the lack of vaccines or antiviral compounds approved for prevention or treatment of human or potential zoonotic CoVs. Anti-CoV drug development has long been challenged by the activity of a 3' to 5' proofreading exoribonuclease unique to CoVs. Recently, a promising nucleoside analogue with broad-spectrum activity against CoVs has been identified. This review will discuss progress made in the development of antiviral nucleoside and nucleotide analogues targeting viral RNA synthesis as effective therapeutics against CoV infections and propose promising strategies for combination therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available